Stocks were indicated higher on Tuesday morning despite sanctions in Russia. Investors still want upside from their investments, but they seem to be looking at individual companies and sectors rather than the broad market as a whole. 24/7 Wall St. reviews dozens of analyst research reports each morning of the week to find new investment and trading ideas for our readers. Some analyst reports cover stocks to buy. Others feature stocks to sell or stocks to avoid.
These are this Tuesday’s top analyst upgrades, downgrades and initiations from Wall Street firms.
AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX) already took at least one downgrade on Monday as its stock fell 41% after the FDA rejected its pain device. Now on Tuesday it was downgraded to Neutral from Overweight at Piper Jaffray.
Alcoa Inc. (NYSE: AA) was reiterated as Buy and the price target was raised to $20 from $17 at Goldman Sachs.
Allstate Corp. (NYSE: ALL) was downgraded to Market Perform from Outperform at William Blair.
Biogen Idec Inc. (NASDAQ: BIIB) was reiterated as Buy and its price target was raised to $385 from $360 (versus a $336.39 close) at Argus.
Boston Scientific Corp. (NYSE: BSX) was started as Neutral at Sterne Agee.